SCHEMBL23537186

SCHEMBL23537186

O=C1CCc2[nH]c(=O)c3ccccc3c21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 14/20 0.53
DYRK1A Q13627 1/20 0.45
TNKS O95271 4/20 0.44
TNKS2 Q9H2K2 4/20 0.44
KDM4E B2RXH2 2/20 0.44
PARP15 Q460N3 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
GPR3 P46089 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
AURKA O14965 1/20 0.38
SERPINE1 P05121 1/20 0.38
CHEK1 O14757 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29824196 1.00 PARP1 (0.53) PARP1DYRK1ATNKSTNKS2KDM4E
SCHEMBL29824193 0.89 PARP1 (0.59) PARP1DYRK1ATNKSTNKS2KDM4E
SCHEMBL29824409 0.89 PARP1 (0.64) PARP1DYRK1ATNKSTNKS2KDM4E
SCHEMBL23537328 0.89 PARP1 (0.64) PARP1DYRK1ATNKSTNKS2KDM4E
SCHEMBL23537356 0.89 PARP1 (0.59) PARP1DYRK1ATNKSTNKS2KDM4E
SCHEMBL30451928 0.81 KDM4E (0.50) PARP1DYRK1ATNKSTNKS2KDM4E
SCHEMBL23537498 0.77 PARP1 (0.45) PARP1DYRK1ATNKSTNKS2KDM4E
SCHEMBL29824598 0.77 PARP1 (0.45) PARP1DYRK1ATNKSTNKS2KDM4E
SCHEMBL23537656 0.75 PARP1 (0.44) PARP1TNKSTNKS2KDM4EPARP15
SCHEMBL29824372 0.75 PARP1 (0.44) PARP1TNKSTNKS2KDM4EPARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230108906-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-04-06 US disclosed
EP-4076648-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-10-26 EP disclosed
CN-115087486-A Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof 爱彼特生物制药公司 2022-09-20 CN disclosed
WO-2021127356-A1 Substituted Bicyclic and Tricyclic Ureas and Amides, Analogues Thereof, and Methods Using Same ARBUTUS BIOPHARMA, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230108906-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME DDC, CDA, HMBS PARP1 2241/4885DYRK1A 2251/4885TNKS 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.